Sjögren’s syndrome — increasingly referred to by clinicians and patient organizations as Sjögren’s disease — is a chronic autoimmune disorder in which the immune system attacks the moisture-producing glands of the body, primarily the salivary and tear glands. Estimates suggest hundreds of thousands to a few million Americans are affected, with women outnumbering men substantially and the average age at diagnosis falling between roughly 40 and 60 according to the NIH’s NIAMS. While the dry eyes and dry mouth that define Sjögren’s can sound mild, the disease is systemic — it can affect joints, lungs, kidneys, nerves, and blood, and it carries a substantially elevated risk of non-Hodgkin lymphoma. (You will see both “syndrome” and “disease” used; they refer to the same condition.)
The Defining Symptoms
Dry eye in Sjögren’s is more than mild irritation. Patients describe a gritty, sandy, or burning sensation, blurry vision that comes and goes, light sensitivity, and a feeling that something is in the eye. Severe cases can produce corneal damage that requires aggressive ophthalmologic management.
Dry mouth (xerostomia) creates difficulty swallowing dry foods, altered taste, dramatic increases in dental cavities (sometimes a decade’s worth in a year), persistent oral yeast infections, and difficulty wearing dentures. The mouth often appears glossy and red rather than wet. Salivary gland enlargement, particularly of the parotids, can be intermittent or chronic.
Other dryness symptoms include dry skin, dry sinuses with frequent crusting, vaginal dryness causing painful intercourse, and a dry trachea contributing to chronic cough. Per Cleveland Clinic, the dryness is often what brings patients in, but systemic features may dominate the long-term course.
Symptoms at a glance
| Category | Common features |
|---|---|
| Eyes | Grittiness, burning, light sensitivity, blurred vision |
| Mouth & dental | Dryness, rapid cavities, yeast infections, gland swelling |
| Other dryness | Skin, sinuses, vaginal dryness, dry cough |
| Systemic | Fatigue, joint pain, Raynaud’s, neuropathy, lung/kidney involvement, brain fog |
Beyond Dryness: Systemic Features
Fatigue affects a large majority of Sjögren’s patients — often around 70 to 80 percent — and is frequently the most disabling symptom. Joint pain — usually inflammatory, with morning stiffness — affects roughly half. Raynaud’s phenomenon, peripheral neuropathy, interstitial lung disease, kidney involvement (typically interstitial nephritis or distal renal tubular acidosis), autoimmune hepatitis, and cytopenias all occur.
Cognitive symptoms — brain fog, difficulty concentrating, word-finding problems — are common and often dismissed. Small-fiber neuropathy producing burning pain in the feet without abnormalities on standard nerve conduction studies has been increasingly recognized. The disease overlaps significantly with other autoimmune conditions; a substantial share of patients have a second autoimmune diagnosis such as lupus, rheumatoid arthritis, or autoimmune thyroid disease. Our lupus guide covers another connective tissue disease that can coexist with Sjögren’s.
Diagnosis
The 2016 ACR/EULAR classification criteria weight several features: anti-SSA/Ro positivity (3 points), a characteristic minor salivary gland biopsy (3 points), abnormal ocular staining (1), abnormal Schirmer test (1), and abnormal unstimulated salivary flow (1). A total of at least four points supports classification in patients with appropriate symptoms. These are classification criteria used to standardize research and support diagnosis — your rheumatologist makes the actual diagnosis in clinical context.
Anti-Ro/SSA antibodies are present in roughly 70 percent of Sjögren’s patients; anti-La/SSB in about 30 to 40 percent. ANA is positive in most patients. Rheumatoid factor — interestingly — is positive in about half of patients, sometimes leading to misdiagnosis as rheumatoid arthritis. Hypergammaglobulinemia, low complement, and elevated ESR are common.
A lip biopsy sampling minor salivary glands and showing focal lymphocytic sialadenitis with a focus score of 1 or higher supports the diagnosis when serology is negative or equivocal. Salivary gland ultrasound is increasingly used as a non-invasive imaging adjunct.
Treating Dryness
Treatment is prescriber-directed and individualized; the options below describe common approaches, not a prescription for any one person. Symptomatic management of dry eye can include preservative-free artificial tears used several times daily, gel lubricants at night, omega-3 supplementation, lid hygiene, and prescription anti-inflammatory drops (such as cyclosporine or lifitegrast). Punctal plugs reduce tear drainage and help selected patients. Severe cases may need autologous serum tears or scleral lenses, managed by an eye specialist.
Dry mouth management involves frequent water sipping, sugar-free gum and lozenges to stimulate flow, saliva substitutes, careful dental care with high-fluoride toothpaste and frequent cleanings, and avoidance of mouth-drying medications when possible. Prescription muscarinic agonists such as pilocarpine or cevimeline can stimulate residual gland function for many patients but may cause sweating and GI side effects — a clinician weighs these trade-offs individually.
Vaginal moisturizers and lubricants help with vulvovaginal dryness; topical estrogens may be appropriate for some postmenopausal women per gynecology guidance.
Systemic Therapy
For systemic disease, hydroxychloroquine is commonly used despite mixed trial evidence — it may help fatigue, arthralgia, and skin manifestations for some patients. Methotrexate, azathioprine, mycophenolate, and rituximab are generally reserved for severe extra-glandular disease (interstitial lung disease, vasculitis, severe peripheral neuropathy, or glomerulonephritis). Which agent, if any, is appropriate is entirely a prescriber’s decision based on organ involvement and individual risk.
Corticosteroids are used for severe organ involvement but are typically tapered as steroid-sparing immunosuppressants take effect; tapers must be individualized and supervised, never self-adjusted. JAK inhibitors and several biologics have been studied in Sjögren’s, and the pipeline is active — verify current, approved options with your rheumatologist rather than assuming a trial drug is available. As of this writing there is no cure and no single treatment that reverses the disease, so be cautious of any source that overpromises.
What treatment aims to do
Realistic goals are to relieve dryness, protect the eyes and teeth from lasting damage, control inflammation and systemic complications, preserve organ function, and improve day-to-day quality of life. Framing expectations this way helps patients and clinicians measure whether a plan is working.
The Lymphoma Risk
Sjögren’s patients have a meaningfully increased risk of non-Hodgkin lymphoma — often cited as roughly 5 to greater than 10 times that of the general population — typically MALT lymphoma of the parotid gland. The lifetime risk is still relatively low in absolute terms, on the order of about 5 to 10 percent in higher-risk subgroups. Risk factors include persistent salivary gland swelling, low complement levels, cryoglobulins, lymphadenopathy, and skin vasculitis.
Patients with these risk factors may need closer monitoring with periodic salivary gland imaging, careful lymph node exams, and prompt evaluation of any persistent gland enlargement. This elevated but monitored risk is one reason rheumatology follow-up matters even when dryness symptoms are stable — it is a reason for surveillance, not for alarm.
When to seek emergency care: Call 911 or go to the nearest emergency room if you experience sudden severe shortness of breath (a possible interstitial lung disease flare or pulmonary embolism), severe abdominal pain, signs of stroke, sudden severe headache, signs of serious infection while on immunosuppressants, or sudden severe eye pain with vision loss. New persistent, painless, or rapidly growing lymph node swelling, and persistent or asymmetric salivary gland enlargement — especially when hard or fixed — warrant prompt (though not necessarily emergency) evaluation for possible lymphoma.
Living With Sjögren’s
Daily routines build around dryness management. Frequent water, eye drops, gum, and humidifiers become habitual. Dental care intensifies — many patients see hygienists every three months and use prescription-strength fluoride. Limiting excess caffeine and alcohol, both of which can worsen dryness, helps.
Fatigue management uses the same strategies as in lupus or fibromyalgia — pacing, prioritizing, regular gentle exercise, sleep hygiene, and sometimes clinician-directed pharmacologic support. Mood disorders are common and treatable, so raise them with your care team. Our medical conditions overview covers chronic disease management more broadly.
When to See a Doctor
Persistent dry eye and dry mouth lasting more than three months, especially with fatigue, joint pain, or rapid dental decay, warrant evaluation. Primary care physicians can initiate the workup with ANA, anti-Ro/La, and basic blood work; a rheumatology referral is appropriate for confirmation and treatment, and it is the specialty best positioned to coordinate long-term care.
Established patients need regular monitoring: rheumatology every 6 to 12 months when stable, annual eye exams, dental checks every 3 to 6 months, and periodic labs to monitor for lymphoma risk factors and organ involvement.
Frequently Asked Questions
Is Sjögren’s syndrome a disability?
It varies. Many patients function well with symptom management. Others experience disabling fatigue, neuropathy, or organ involvement that limits work and daily activities. Severe disease with significant systemic manifestations can qualify for disability benefits in the US; eligibility depends on documentation and program rules.
Can Sjögren’s go into remission?
True remission is uncommon — most patients have ongoing dryness and require lifelong symptom management. However, periods of low disease activity with minimal systemic features are achievable for many patients, and inflammatory features often respond well to clinician-directed therapy.
Is Sjögren’s syndrome inherited?
Genetic susceptibility plays a role, but Sjögren’s is not directly inherited. First-degree relatives have a somewhat elevated risk of autoimmune disease in general. Most patients have no family history of Sjögren’s specifically.
What triggers Sjögren’s flares?
Reported triggers include viral infections, dehydration, certain medications (antihistamines, decongestants, anticholinergics, diuretics), surgical stress, and emotional stress. UV exposure can trigger lupus-like flares in patients with overlap features. Triggers differ from person to person.
Is it called Sjögren’s “syndrome” or “disease” now?
Both terms are in use for the same condition. NIH’s NIAMS and the Sjögren’s Foundation increasingly use “Sjögren’s disease” to emphasize that it is a systemic illness, while “Sjögren’s syndrome” remains widely recognized.
The Bottom Line
Sjögren’s syndrome is more than a dryness condition — it is a systemic autoimmune disease with a distinctive, monitored lymphoma risk. Daily symptom management of dry eyes and dry mouth, prompt attention to dental care, and regular rheumatology follow-up remain the foundation of long-term care. Watch for new lymph node enlargement, persistent salivary gland swelling, lung symptoms, or numbness — those features change management. Modern recognition of the systemic nature of Sjögren’s, an expanding research pipeline, and growing patient communities all make the disease more manageable than a decade ago, even though there is still no cure and the toolkit remains incomplete.
TL;DR: Sjögren’s (now often called Sjögren’s disease) is a systemic autoimmune disorder — dry eyes and mouth plus fatigue, joint pain, neuropathy, and possible organ involvement. Diagnosis blends symptoms, anti-SSA/Ro antibodies, eye tests, and sometimes a lip biopsy. Treatment is individualized and prescriber-directed: dryness care, protective dental and eye care, and medications like hydroxychloroquine or immunosuppressants for systemic disease. There is an increased, monitored lymphoma risk. See a rheumatologist; there is no cure.
This article is for general education only and is not medical advice. Do not start, stop, or change any medication on your own. Diagnosis and treatment must be individualized by a rheumatologist or other qualified clinician, and current treatment options change — verify them with your care team.
Sources
- NIH — National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS): Sjögren’s Disease
- Sjögren’s Foundation — Patient education and clinical practice guidelines
- MedlinePlus — Sjögren’s Syndrome
- Cleveland Clinic — Sjögren’s Syndrome overview